All In MedTech

Device Trial Radar · NCT01378611

Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy?

Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy? A Randomized Clinical Study.

Last checked: Nov 20, 2026Latest source record: Jun 29, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

45

Planned (sponsor's estimate)

Start

Mar 2006

Primary completion

Mar 2012

Study completion Mar 2013

Sponsor

Lead sponsor
Epilepsiecentrum KempenhaegheNot on our public-company list
Sponsor type
Industry
Collaborators
Maastricht University Medical Center
First posted
Jun 22, 2011

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical randomized controlled observer blinded add-on design. Additionally there will be a non-controlled follow-up phase of the study. Children (Age 4-18 years) with intractable epilepsy, and not eligible for resective surgery will be treated with VNS. Aim of the study: 1. To evaluate tolerability and effectiveness of VNS in children with intractable epilepsy and cognitive and behavioural problems in a controlled study. 2. To evaluate the effect of VNS on the immune system which, in its turn, will lead to changes in the serotonin metabolic pathway 3. To link the therapeutic effect of VNS to changes in the serotonin (5HT) metabolic pathway. In addition the investigators hope to detect some markers of immune and neurotransmitter function that enable us to predict 1) Neuronal cell loss in relation to cognitive decline 2) the response to therapeutic treatment of VNS. Hypothesis: The investigators aim to explore neuronal correlates for cognitive morbidity in children with intractable epilepsy and to relate this to morphologic changes, biochemical markers, and to epilepsy characteristics. Correction of the "stressed" pro-inflammatory status of monocytes/macrophages via an electrical stimulation of the vagus nerve will prevent/ameliorate seizures as well as behavioural mood symptoms in children with refractory epilepsy, characterized by the "pro-inflammatory monocyte signature"

Conditions

  • Refractory Epilepsy in Children

Interventions

  • Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USADevice

    The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. seizure frequency reduction of 50% or moreTime frame: after 3 and 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Maastricht University Medical Center

    Maastricht, Limburg, Netherlands

  • Epilepsiecentrum Kempenhaeghe

    Heeze, North Brabant, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.